000			03330nam a22003737a 4500
008			220706s20222022 xxu||||| |||| 00| 0 eng d
022			_a2666-6677
024			_a10.1016/j.ajpc.2022.100345 [doi]
024			_aPMC9097618 [pmc]
024			_aS2666-6677(22)00029-0 [pii]
040			_aOvid MEDLINE(R)
099			_a35574517
245			_aThe potential population health impact of treating REDUCE-IT eligible US adults with Icosapent Ethyl.
251			_aAmerican Journal Of Preventive Cardiology. 10:100345, 2022 Jun.
252			_aAm J Prev Cardiol. 10:100345, 2022 Jun.
253			_aAmerican journal of preventive cardiology
260			_c2022
260			_fFY2022
260			_p2022 Jun
265			_sepublish
265			_tPubMed-not-MEDLINE
266			_d2022-07-06
520			_aConclusions: Treating all REDUCE-IT eligible US adults has substantial medication costs but could prevent a substantial number of ASCVD events and associated direct costs. Indirect cost savings by preventing events could outweigh much of the incurred direct costs. Copyright © 2022 The Author(s).
520			_aMethods: We derived REDUCE-IT eligible cohorts in (1) the National Health and Nutrition Examination Surveys (NHANES) 2009-2014 and (2) the Optum Research Database (ORD). Population sizes were obtained from NHANES and observed first event rates (composite of cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, unstable angina requiring hospitalization, or coronary revascularization) were estimated from the ORD. Hazard ratios from REDUCE-IT USA estimated events prevented with IPE therapy. The National Inpatient Sample estimated event costs (facility and professional) and daily IPE treatment cost was approximated at _4.59.
520			_aObjective: To explore the population health impact of treating all US adults eligible for the Reduction of Cardiovascular Events with Icosapent Ethyl-Intervention Trial (REDUCE-IT) with icosapent ethyl (IPE), we estimated (1) the number of ASCVD events and healthcare costs that could be prevented; and (2) medication costs.
520			_aResults: We estimate 3.6 million US adults to be REDUCE-IT eligible, and the observed five-year first event rate without IPE of 19.0% (95% confidence interval [CI] 16.6%-19.5%) could be lowered to 13.1% (95% CI 12.8%-13.5%) with five years of IPE treatment, preventing 212,000 (uncertainty range 163,000-262,000) events. We projected the annual IPE treatment cost for all eligible persons to be _6.0 billion (95% CI _4.7- _7.5 billion), but saving _1.8 billion annually due to first events prevented (net annual cost _4.3 billion). The total five-year event rate (first and recurrent) could be reduced from 42.5% (95% CI 39.6%-45.4%) to 28.9% (95% CI 26.9-30.9%) with five years of IPE therapy, preventing 490,000 (uncertainty range 370,000-609,000) events (net annual cost _2.6 billion).
546			_aEnglish
651			_aMedStar Health Research Institute
657			_aJournal Article
700			_aWeintraub, William S
790			_aAbrahamson D, Andrade KE, Bhatt DL, Bress AP, Derington CG, Fan W, Herrick JS, Jiao L, Johnson J, Philip S, Weintraub WS, Wong ND
856			_uhttps://dx.doi.org/10.1016/j.ajpc.2022.100345 _zhttps://dx.doi.org/10.1016/j.ajpc.2022.100345
942			_cART _dArticle
999			_c435 _d435